Hepatitis C News and Research

Latest Hepatitis C News and Research

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

Should we be screening blood for hepatisi G?

Hepatitis G virus was identified in 1995. Some little research was carried out on the virus and the US Food and Drug Administration (FDA) declared it a non-harmful virus in 1997. Researchers in Saudi Arabia, writing in the International Journal of Immunological Studies present evidence to suggest that this may have been the wrong decision.

22 Aug 2011

Saffron promotes apoptosis and inhibits growth of cancerous cells

New research suggests that saffron provides a significant chemopreventive effect against liver cancer in animal models. When saffron was administered to rats with diethylnitrosamine (DEN)-induced liver cancer an inhibition of cell proliferation and stimulation of apoptosis was observed. Full findings appear in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Aug 2011

Hospital roundup: Catholic facilities losing nuns' leadership; Georgia infection rates; new VA system for Louisiana

In 1968, nuns or priests served as chief executives of 770 of the country's 796 Catholic hospitals, according to the Catholic Health Association. Today, they preside over 8 of 636 hospitals. ... The leadership shift has stirred angst in many Catholic hospitals about whether the values imparted by the nuns, concerning the treatment of both patients and employees, can withstand bottom-line forces without their day-to-day vigilance.

22 Aug 2011

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

Today AIDS Healthcare Foundation (AHF) decried the fact that the recent campaign by Gilead Sciences Inc. to obtain approval by the U.S. Food & Drug Administration for Truvada as PrEP (pre-exposure prophylaxis) has led to a "black market" for the drug in Florida.

20 Aug 2011

Emory team identifies conditions that make memory T cells slip away during chronic infections

After recovering from the flu or another acute infection, your immune system is ready to react quickly if you run into the same virus again. White blood cells called memory T cells develop during the infection and help the immune system remember the virus and attack it if it comes back.

19 Aug 2011

Powerful X-rays help develop new drug treatment for malignant melanoma

Powerful X-ray technology developed at the U.S. Department of Energy's (DOE's) national laboratories is revealing new insights into diseases ranging from Alzheimer's to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, the deadliest form of skin cancer.

19 Aug 2011

New book on hemophilia, unintended consequences of medical progress

The Bleeding Disease: Hemophilia and the Unintended Consequences of Medical Progress (John Hopkins University Press) is the new book by NJIT Associate Professor Stephen Pemberton. The book recounts the promising and perilous history of medical and social efforts to manage hemophilia in 20th-century America.

19 Aug 2011

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Medgenics second quarter net loss increases to $2.32 million

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2011.

12 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended June 30, 2011.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Pharmasset declares two-for-one split of common stock

Pharmasset, Inc. announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend.

9 Aug 2011

MAVS prion-like proteins are involved in innate immunity: Discovery

A person's ability to battle viruses at the cellular level remarkably resembles the way deadly infectious agents called prions misfold and cluster native proteins to cause disease, UT Southwestern Medical Center researchers report.

9 Aug 2011

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person's central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

GenMark Diagnostics second quarter revenues increase to $901,000

GenMark Diagnostics, Inc. today reported financial results for the second quarter ended June 30, 2011.

5 Aug 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Should we be screening blood for hepatisi G?

Saffron promotes apoptosis and inhibits growth of cancerous cells

Hospital roundup: Catholic facilities losing nuns' leadership; Georgia infection rates; new VA system for Louisiana

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

Emory team identifies conditions that make memory T cells slip away during chronic infections

Powerful X-rays help develop new drug treatment for malignant melanoma

New book on hemophilia, unintended consequences of medical progress

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Medgenics second quarter net loss increases to $2.32 million

Sinovac second quarter sales increase 52.5% to $15.7 million

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

China Pharma second quarter revenue increases 18% to $19.6 million

FDA approves Gilead's Complera for treatment of HIV-1 infection

Pharmasset declares two-for-one split of common stock

MAVS prion-like proteins are involved in innate immunity: Discovery

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Inhibitex second quarter net loss decreases to $5.3 million

Idera second quarter net loss increases to $6.3 million

GenMark Diagnostics second quarter revenues increase to $901,000

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in